决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
100.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
非小细胞肺癌基因治疗的进展：当前方法与未来前景
英文原题：Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects.
查看英文原题
Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
非小细胞肺癌（NSCLC）是全球癌症相关死亡的首要原因，其特点是诊断较晚且对传统疗法耐药。基因治疗已成为NSCLC治疗的一种有前景的替代方法，尤其适用于传统治疗已无效的晚期患者。本文深入探讨NSCLC基因治疗的当前进展，包括基因替代和肿瘤抑制基因疗法、基因沉默、CRISPR/Cas9基因编辑，以及CAR-T 细胞疗法介导的免疫调节。此外，本文还讨论了NSCLC基因治疗面临的挑战和未来前景。
展开英文摘要原文
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, characterized by late diagnosis and resistance to conventional therapies. Gene therapy has emerged as a promising alternative for NSCLC therapy, especially for patients with advanced disease who have exhausted conventional treatments. This article delved into the current developments in gene therapy for NSCLC, including gene replacement and tumor suppressor gene therapy, gene silencing, CRISPR/Cas9 gene editing, and immune modulation with CAR-T cell therapy.
In addition, the challenges and future prospects of gene-based therapies for NSCLC were discussed.
论文信息
- 作者
- Ziółkowska-Suchanek I、Rozwadowska N
- 单位
- Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland.Poland
- 文献类型
- 综述
- 期刊
- Genes2025 May 12
- 原文标识
- PubMed 40428391 · DOI 10.3390/genes16050569